OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
November 21, 2022 02:00 ET
|
OKYO Pharma LTD
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE...
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
November 10, 2022 06:00 ET
|
OKYO Pharma LTD
Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology...
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
September 08, 2022 09:25 ET
|
OKYO Pharma LTD
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited: Result of Annual General Meeting
September 07, 2022 09:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative...
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
August 30, 2022 02:00 ET
|
OKYO Pharma LTD
OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market...
OKYO Pharma Limited - Final audited results for the year ended 31 March 2022
August 16, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March...
OKYO Pharma Limited - PDMR Dealing
June 09, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and...
OKYO Pharma Limited - PDMR Dealing
May 20, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing
May 19, 2022 16:00 ET
|
OKYO Pharma LTD
LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused on the discovery and development of novel...
OKYO Pharma Limited - PDMR Dealing
May 18, 2022 06:35 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat...